Key result
Cilostazol and levosimendan, alone or in combination, significantly restored MDA levels, SOD activity, GSH levels, and lung injury scores compared to control following lower limb ischemia-reperfusion (p<0.05).
Why the study?
Does pretreatment with cilostazol and levosimendan reduce lung remote organ damage after lower limb ischemia/reperfusion in a rat model?
Does pretreatment with cilostazol and levosimendan reduce lung remote organ damage after lower limb ischemia/reperfusion in a rat model?
p-value: p=<0.05
Supports antioxidant effects in experimental remote lung injury; leaves open clinical relevance pending human studies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gökhan Önem (2012) studied Lung injury induced by lower limb ischemia-reperfusion (n=35). Cilostazol and levosimendan vs. Ischemia/reperfusion (I/R) control and sham-operated groups was evaluated on Malondialdehyde (MDA) levels, superoxide dismutase (SOD) activity, glutathione (GSH) levels, and histopathological lung injury scores (p=<0.05). Cilostazol and levosimendan, alone or in combination, significantly restored MDA levels, SOD activity, GSH levels, and lung injury scores compared to control following lower limb ischemia-reperfusion (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: